.png)
HRSA is back with a new version of its 340B rebate pilot, this time targeting a January 2027 start. If the topic sounds familiar, that's because it is: this is the agency's second attempt at the same basic idea. Here's what's actually in the new notice and what it means for your program.
The 340B Rebate Model Pilot Program would change how covered entities receive 340B pricing on a defined set of drugs, those selected for the 2026 and 2027 Medicare Drug Price Negotiation Program cycles. Instead of buying at the discounted 340B ceiling price up front, participating entities would purchase at full wholesale acquisition cost (WAC) and then recover the difference through a rebate submitted after the fact.
This is not a change to who qualifies for 340B or which drugs are covered by the program broadly. It's a change to the mechanism of discount delivery for a specific, limited drug set tied to Medicare's negotiation timeline.
The mechanics matter more than the headline. Under the current notice, covered entities submit claims data to manufacturer-designated vendors within 45 days of the dispense date, with exceptions built in for documented extenuating circumstances. Manufacturers then have 10 days to either pay the rebate or deny the claim with a written explanation.
Denials are not unlimited. Manufacturers cannot reject a rebate claim on diversion or Medicaid duplicate discount grounds, those remain compliance issues handled through existing channels, not reasons to withhold payment. Legitimate denial reasons include situations where the Medicare maximum fair price should have applied instead, or where another covered entity already received a rebate on the same claim.
The practical effect for finance teams: a period where cash is tied up in full-price purchases before the rebate lands. For 340B program staff: a new data submission cadence to track and audit against.
HRSA tried this once before, targeting a January 2026 start. A federal court in Maine issued a nationwide injunction before that version took effect, ruling that HRSA hadn't adequately explained its decision-making or accounted for the cost to hospitals under administrative law standards. The case was later vacated and sent back to HRSA to reassess.
This new notice is HRSA's response to that remand. The agency appears to be building a more detailed record this time, though the core trade-off it's navigating, balancing entities' reliance on upfront pricing against its own oversight goals, is the same one from round one. Whether this version holds up is still an open question worth watching.
We track manufacturer rebate plan approvals as they're finalized and flag which of your purchasing relationships are affected. Our job is translating the notice's requirements into your actual claims workflow and cash flow planning. Your job is deciding how much operational change to make now versus waiting for the picture to clarify further. We'll keep you current on both.
No. It's limited to drugs selected for the 2026 and 2027 Medicare drug price negotiation cycles, and only for manufacturers approved to participate.
They're required to provide written rationale. If the denial doesn't match one of the permitted reasons, that's worth escalating.
Possibly. The prior version didn't reach its start date, so it's reasonable to expect this timeline could shift too.
Not yet, unless you've confirmed a specific manufacturer relationship is affected. Start with the mapping step above
